Prafull Ghatage

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Rucaparib Maintenance Treatment, Medicine, Recurrent Ovarian Carcinoma +7

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 599 citations · Full text

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 432 citations · Full text

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye et al. · Journal of Clinical Oncology · 2010 · 404 citations

Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ellen L. Goode, Matthew S. Block, Kimberly R. Kalli et al. · JAMA Oncology · 2017 · 388 citations · Full text